Inthera Bioscience Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11.2M

  • Investors
  • 5

Inthera Bioscience General Information

Description

Developer of targeted small molecule therapies designed to treat solid tumors. The company's therapies are focused on the development of novel oral agents blocking aberrant cell signaling in solid tumors by leveraging a proprietary platform to rationally design protein-protein interaction inhibitors, enabling the medical community to improve outcomes involving cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Corporate Office
  • Schärenmoosstrasse 77
  • Schlieren
  • 8052 Zurich
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inthera Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 26-Jun-2018 $11.2M 000.00 000.00 Completed Pre-Clinical Trials
2. Seed Round 14-Dec-2015 00.000 00.000 Completed Product Development
1. Seed Round 30-Apr-2014 $226K $226K 00.000 Completed Generating Revenue
To view Inthera Bioscience’s complete valuation and funding history, request access »

Inthera Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 000.00 000.00 00 000.00 00.000
Seed 00,000 000.00 000.00 00 000.00 0.000
Seed 277,776 $7.98 $7.98 1x $7.98 20.84%
Ordinary 25,000 $9.34 $9.34 1x $9.34 1.88%
To view Inthera Bioscience’s complete cap table history, request access »

Inthera Bioscience Patents

Inthera Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4168014-A1 Oxopiperazine derivatives for the treatment of cancer Pending 19-Jun-2020 0000000000
US-20230226044-A1 Oxopiperazine derivatives for the treatment of cancer Pending 19-Jun-2020 0000000000
US-20190185449-A1 Oxopiperazine derivatives Active 15-Dec-2017 0000000000
US-20220213057-A1 Oxopiperazine derivatives Active 15-Dec-2017 0000000000
US-11306068-B2 Oxopiperazine derivatives Active 15-Dec-2017 C07D401/06 00
To view Inthera Bioscience’s complete patent history, request access »

Inthera Bioscience Executive Team (7)

Name Title Board Seat
Ulrich Kessler Co-Founder & Co-Chief Executive Officer
Bernd Hentsch Ph.D Chief Development Officer
Paul Cloos Ph.D Co-Chief Scientific Officer
Ralph Lindemann Ph.D Co-Chief Scientific Officer
Paramjit Arora Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

Inthera Bioscience Board Members (10)

Name Representing Role Since
Anker Lundemose Ph.D Self Board Member 000 0000
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Karl Rothweiler Aglaia Oncology Funds Board Member 000 0000
Klaus Schollmeier Ph.D Self Chairman 000 0000
Mark Krul Ph.D Aglaia Oncology Funds Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Inthera Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inthera Bioscience Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aglaia Oncology Funds Venture Capital Minority 000 0000 000000 0
Eva Capital Accelerator/Incubator Minority 000 0000 000000 0
Microsoft for Startups Accelerator/Incubator Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Novo Holdings Asset Manager Minority 000 0000 000000 0
To view Inthera Bioscience’s complete investors history, request access »

Inthera Bioscience FAQs

  • When was Inthera Bioscience founded?

    Inthera Bioscience was founded in 2013.

  • Who is the founder of Inthera Bioscience?

    Ulrich Kessler and Paramjit Arora are the founders of Inthera Bioscience.

  • Who is the CEO of Inthera Bioscience?

    Ulrich Kessler and Martin Bonde Ph.D are the CEOs of Inthera Bioscience.

  • Where is Inthera Bioscience headquartered?

    Inthera Bioscience is headquartered in Zurich, Switzerland.

  • What is the size of Inthera Bioscience?

    Inthera Bioscience has 6 total employees.

  • What industry is Inthera Bioscience in?

    Inthera Bioscience’s primary industry is Drug Discovery.

  • Is Inthera Bioscience a private or public company?

    Inthera Bioscience is a Private company.

  • What is the current valuation of Inthera Bioscience?

    The current valuation of Inthera Bioscience is 000.00.

  • What is Inthera Bioscience’s current revenue?

    The current revenue for Inthera Bioscience is 000000.

  • How much funding has Inthera Bioscience raised over time?

    Inthera Bioscience has raised $15.1M.

  • Who are Inthera Bioscience’s investors?

    Aglaia Oncology Funds, Eva Capital, Microsoft for Startups, M Ventures, and Novo Holdings have invested in Inthera Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »